medigraphic.com
ISSN 1561-3062 (Electronic)

2012, Number 2

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2012; 38 (2)

Intralesion application of the Cuban 2bHr Alfa-Interferon (Heberon Alfa R® in the treatment of genital warts

Baladrón CI, Barbón GZ, Solares AAM, Valenzuela SC, García IE, Martínez MA

Language: Spanish
References: 44
Page:
PDF size: 616.70 Kb.


ABSTRACT

Introduction: the genital condyloma is the more frequent clinical expression or the human papilloma virus. From the available alternative of treatment there is not one of election and totally effective.
Objective: to describe the safety and the effect of recombinant alfa-Interferon in treatment of genital warts.
Methods: a quasi-experimental study was conducted in 216 women and in 111 men. The above mentioned Interferon was applied in the basement of warts at a dose of 10 millions of international units weekly during 8-16 weeks. Patients were seen in the "Ramón González Coro" Gynecology and Obstetrics Hospital of La Habana from March, 2009 to June, 2011. In each application the adverse events were reported, estimating its frequency distribution. The objective response was assessed according to the percentage of reduction of the sum of the great diameters at 4, 8 and 16 weeks after the application. Recurrence was assessed at 24 months using the Kaplan-Meier curve.
Results: there was response to treatment in the 81.5 % of patients. More than 60 % had a total response where only the 11.1 % were recurrent. The more frequent adverse events were: fever, headache and chivers of slight or moderate intensity.
Conclusions: the application of Interferon around injury may be considered an safe and effective alternative in treatment of genital warts.


REFERENCES

  1. Shiffman MH, Brinton LA. The Epidemiology of Cervical carcinogenesis. Cancer 1995;76:1888-1901.

  2. Sherman ME, Kurman RJ. Intraepithelial carcinoma of the cervix: reflections on half a century of progress. Cancer. 1998;83:2243-6.

  3. Costa LJ, Silveira FR, Batista JM, Birman EG. Human papilloma virus—its association with epithelial proliferative lesions. Braz Dent J. 1994;5(1):5-10.

  4. Munoz N, Bosch X, de Sanjose S., Herrero R, Castellsague X, Shah KV. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med. 2003;348:518-27.

  5. American Cancer Society. Cancer Facts and figures 2007. Atlanta.American Cancer Society;2007.

  6. Von Krogh G, Lacey CJN, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Inf. 2000;76;162-8.

  7. Guidelines for the Medical Management of Genital HPV and/or Genital Warts in Australia and New Zaeland. 4th Edition-2004. Viral Sexually Transmitted Infection Education Foundation;2004.

  8. Bylaite M, Ruzicka T. Pearly Penile Papules. N Engl J Med. 2007;357(7).

  9. Nicolas Kluger, Olivier Dereure. Penile Papules. N Engl J Med. 2009;360(13).

  10. Chih-Chieh Chan, Hsien-Ching Chiu. Vestibular Papillomatosis. N Engl J Med. 2008;358(14).

  11. Reichman RC, Oakes D, Bonnez W. Treatment of Condyloma acuminatum with three different interferons administered intralesionally: a double-blind, placebo-controlled trial. Ann Intern Med. 1988;108:675-9.

  12. Eron LJ, Juhson F, Tucker S. Interferon therapy for condylomata acuminata. N Engl J Med. 1986;315:1059-64.

  13. Deuñas L, Alcantud V, Alvarez F. Use of Interferon-a in laryngeal papillomatosis: eight years of the Cuban national programme. The Journal of Laryngology and Otology. 1997;111:134-40.

  14. Sagaró B, Selman-Houssein E, Martínez R. Uso del Interferón leucocitario humano en las verrugas plantares. Interferón y Biotecnología 1988;5 (1):59-65.

  15. Hagensee ME. Infection with human papillomavirus: update on Epidemiology, Diagnosis, and Treatment. Curr Infect Dis Rep. 2000 Feb;2 (1):18-24.

  16. Severson J, Evans TY, Lee P, Chan Ts T, Arany I, Tyring SK. Human Papillomavirus infections: Epidemiology, Pathogenesis, and therapy. J Cutan Med Surg. 2001 Jan;5 (1):43-60.

  17. Reichel RP, Fitz R, Neumann R, Pohl-Markl H, Pichler E, Hoffer Z. Clinical study with recombinant interferon gamma versus interferon alpha-2c in patients with condylomata acuminate. Int J STD AIDS. 1992;3(5):350-4.

  18. Höpel RM, Sandbichler M, Zelger BW, Conrad FG, Fritsch PO. Adjuvant treatment of recalcitrant genitoanal warts with systemic recombinant interferon-alpha-2c. Acta Derm Venereol. 1992;72 (5): 383-6.

  19. Itri L M. The interferons. Cancer. 1992;70 (4 Suppl):940-5.

  20. Basso P, Verdi F. Beta interferon therapy of HPV infections of the female genital tract. Minerva Ginecol. 1992;44 (4):181-4.

  21. Davis BE, Noble MJ. Initial experience with combined interferon-alpha 2B and carbon dioxide laser for the treatment of condylomata acuminata. J Urol. 1992;147 (3):627-9.

  22. Reid R, Greenberg MD, Pizzuti DJ, Omoto KH, Rutledge LH, Soo W. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol. 1992;166(3):815-20.

  23. Fierlbeck G, Rassner G, Pfister H. Condylomata acuminata in children-detection of HPV 6/11 and 2. Local therapy with interferon-beta hydrogel. Hautarzt. 1992;43(3):148-51.

  24. Resta L, Troia M, Russo S, Colucci GA, Sabatini R, Loiudice L, et al. Variations of lymphocyte sub-populations in vulvar condylomata during therapy with beta-interferon. Eur J Gynaecol Oncol. 1992, 13 (5):440-4

  25. Zwiorek L, Schmidt-Rhode P, Goerke K, Schulz KD. Condylomata acuminata and associated infections—possibilities for therapy with interferon. Zentralbl Gynakol. 1992;114(8):409-13.

  26. Backe J, Roos T, Kaesemann H, Martius J, Ott M. Local therapy and adjuvant interferon therapy in genital papilloma virus infections. Gynakol Geburtshilfliche Rundsch. 1995;35 (2):79-84.

  27. Mistrangelo M, Cornaglia S, Pizzio M, Rimonda R, Gavello G, Dal Conte I, Mussa A. Immunostimulation to reduce recurrence after surgery for anal condyloma acuminata: a prospective randomized controlled trial. Colorectal Dis;2009.

  28. Guías para el tratamiento de las infecciones de transmisión sexual. Ginebra, Suiza: Catalogación por la Biblioteca de la OMS;2001.

  29. Guías de Buena Práctica Clínica en infecciones víricas dermatológicas. Organización Medica Colegial de España .OMC. Editorial Internacional Marketing and comunication, S.A;2011.

  30. García-García I, González-Delgado CA, Valenzuela-Silva C, Hernández-Bernal F, Ferrero-Bibilonia J, Soto-Hernández R, et al. Bioequivalence of Two Recombinant Interferon á-2b Liquid Formulations in Healthy Male Volunteers. Drugs R D. 2004;5 (5):271-80.

  31. Cancer therapy Evaluation Program, Common Terminology criteria for Adverse events, Version 3.0, DCTD,NCI,NIH,DHHS, Marcg 31, 2003. Publish Date: June 10, 2003. Disponible en: http://www.ctep.cancer.gov

  32. Armitage P, Berry G. Estadística para la Investigación Biomédica. Barcelona: Doyma,;1992.

  33. Szeimies RM, Schleyer V, Moll I, Stocker M, Landthaler M, Karrer S. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation-A phase III, prospective, randomized, bicentric, double-blind study. Dermatol Surg. 2009;35(5):757-64.

  34. Szeimies, Rolf-Markus. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation-A phase III, prospective, randomized, bicentric, double-blind study. Dermatol Surg. 2009;35 (5):757-64.

  35. Yan, Jun, Chen, Sheng-Li, Wang, Hai-Na, et al. Meta-analysis of 5 % imiquimod and 0.5 % podophyllotoxin in the treatment of condylomata acuminate. Dermatology. 2006;213(3):218-23.

  36. Cortés JR, Arratia J, Martínez R, Gómez L. Extensive condyloma acuminata of the penis successfully treated with 5% imiquimod cream. Actas Urol Esp. 2007;31 (3):276-8.

  37. Herrera S, Correa LA, Wolff JC, Gaviria A, Tyring SK, Sanclemente G. Effect of imiquimod in anogenital warts from HIV-positive men. J Clin Virol. 2007;39(3):210-4.

  38. Campaner AB, Santos RE, Galvão MA, Longo B, Geni W, Aoki, T. Effectiveness of imiquimod 5% cream for treatment of extensive anogenital warts in a seven-year-old child. Pediatr Infect Dis J. 2007;26(3):265-6.

  39. Garland SM, Waddell R, Mindel A, Denham IM, McCloskey JC. An open-label phase II pilot study investigating the optimal duration of imiquimod 5 % cream for the treatment of external genital warts in women. Int J STD AIDS. 2006;17(7):448-52.

  40. Lauta VM. Update on the use of interferons in clinical practice. Clin Ter. 1995 Jun-Jul;146(6-7):393-448.

  41. Scheinfeld, Noah, Lehman, Daniel S. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12(3):5.

  42. Ralph P, Insinga, Erik J. Dasbach, and Evan R. Myers. The Health and Economic Burdenof Genital Warts in a Set of Private Health Plans in the United States. Burden of Genital Warts • CID. 2003:36.

  43. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. 2004;70(12):2335-42.

  44. De Jong A, ONeill T, Khanb AY, Kwappenberg KMC, Chisholm SE, Whittle NR, et al. Enhancement of human papilomavirus (HPV) type 16 E6 and E7-specific T-cel immunity in healthy volunteers through vaccination with TA-CIN, an HPV 16 L2E7E6 fusion protein vaccine. Vaccine. 2002;20:356-64.




2020     |     www.medigraphic.com